HPTN Presentations at CROI 2024 00131 - Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083 0789 - No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for HIV PrEP in HPTN 083 00128 - Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083
